2 results
Approved WMOCompleted
To establish preliminary safety and tolerability of single- and multiple-ascending oral doses of MYK 491 in ambulatory patients with stable heart failure with reduced ejection fraction (HFrEF)
Approved WMORecruiting
The study is divided in two phases.The primary objective of phase I of the study is to evaluate the safety and toxicity of the infusion of ex vivo expanded UCB-NK cells, both with and without sc IL-2 following immunosuppressive conditioning therapy…